# A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies

> **NCT01232712** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vaxil Therapeutics Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** ImMucin, hGM-CSF

## Key facts

- **NCT ID:** NCT01232712
- **Lead sponsor:** Vaxil Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2013-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01232712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01232712, "A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01232712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*